Clinical Trials
4 trialsNCT02189720 2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT02970162 2018-12-24
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01377922 2018-01-04
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01511978 2017-07-11
DAPPER
Jacobus Pharmaceutical
Phase 2 Completed